Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment

Lancet

Volumn 353, Issue 9167, 1999, Pages 1834-1837

  Lebech, Marten ^a,d   Andersen, Ole ^b   Christensen, Niels Christian ^c   Werte, Jens ^d   Nielsen, Wans Erik ^e   Peitersen, Birgit ^f   Rechnitzer, Catherine ^g   Larsen, Severin Olesen ^h   Nørgaard Pedersen, Bent ⁱ   Petersen, Eskild ^j  

^a Statens Serum Instit   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Clinical Biochemistry   (Denmark)

^d STATENS SERUM INSTITUT   (Denmark)

^e HILLERØD HOSPITAL   (Denmark)

^f Sonderborg County Hospital   (Denmark)

^g GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^h GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

ⁱ HVIDOVRE HOSPITAL   (Denmark)

^j Rigshospitalet   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY;

ARTICLE; BLOOD SAMPLING; CONGENITAL TOXOPLASMOSIS; FIRST TRIMESTER PREGNANCY; HUMAN; MOTHER FETUS RELATIONSHIP; NEWBORN SCREENING; NONHUMAN; PHENYLKETONURIA; PREGNANCY COMPLICATION; PRENATAL SCREENING; PRIORITY JOURNAL; SCREENING; SEROCONVERSION; TOXOPLASMA GONDII;

EID: 0033614649     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)11281-3     Document Type: Article

References (23)

1. Zuber P, Jacquier P. Epidemiologie de la toxoplasmose: situation au niveau mondial. Schweiz Med Wochenschr 1995; 125 (suppl): 19-22.
2. Koppe JG, Rothova A. Congenital toxoplasmosis: a long-term followup of 20 years. Int Ophthalmol 1989; 13: 387-90.
3. McAuleyJ, Boyer KM, Patel D, et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago collaborative treatment trial. Clin Infect Dis 1994; 18: 38-72.
4. Wilson CB, Remington JS, Stagne S, et al. Development of adverse sequelae in children born with subclinical congenital toxoplasma infection. Pediatrics 1980; 6: 767-74.
5. Jeannel D, Costagliola D, Niel G, Hubert B, Dam's M. What is known about the prevention of congenital toxoplasmosis? Lancet 1990; 336: 359-61.
6. Desmonts G. Prevention of toxoplasmosis: observations on follow-up experience in France. Prog Clin Biol Res 1985; 163B: 333-37.
7. Aspöck H, Flamm H. 15 years of toxoplasmosis surveillance of pregnant women in Austria: an exemplary results in the prevention of neonatal infection. Österr Krankenpflegez 1990; 43: 252-53.
8. Desmonts G, Couvreur J. Toxoplasmosis in pregnancy and its transmission to the fetus. Bull N Y Acad Sei 1974; 50: 146-59.
9. Foulon W, Naessens A, Volckaert M, Lauwers S, AmyJJ. Congenital toxoplasmosis: a prospective survey in Brussels. Br J Obstet Gynaecol 1984; 91:419-23.
10. Desmonts G, Couvreur J. Congenital toxoplasmosis: a prospective study of 378 pregnancies. N Engl JMed 1974; 290: 1110-16.
11. Forsgren M, Gille E, Ljungstrom I, Nokes DJ. Toxoplasmagondii ntibodies in pregnant women in Stockholm in 1969, 1979, and 1987. Lancet 1991; 337: 1413-14.
12. Ades AE, Nokes DJ. Modeling age- and time-specific incidence from seroprevalence: toxoplasmosis. AmJEpidemiol 1993; 137: 1022-34.
13. Guerina NG, Hsu HW, Meissner HC, et al. Neonatal sérologie screening and early treatment for congenital Toxoplasma gondii infection. N Engl J Med 1994; 33: 1858-63.
14. Kemp DT, Ryan S. Otoacustic emission test in neonatal screening programmes. Acta Otolaryngol 1991; 482 (suppl): 73-84.
15. Lebech M, Petersen E. Detection by enzyme immunosorbent assay of Toxoplasma gondii IgG antibodies in dried blood spots on PKU-filter paper from newborns. ScandJ Infect Dis 1995; 27:259-63.
16. Harning D, Spenter H, Metsis A, et al. Recombinant Toxoplasma gondii SAG l (P30) expressed in Eschericia coli is recognized by human Toxoplasma -specific IgM and IgG antibodies. J Clin Immunol Lab Diagn 1996; 3: 355-57.
17. Lebech M, Dutton G, Gilbert R, et al. Classification system and case definitions of Toxoplasma infection in immunocompetent pregnant women and their congenitally infected offspring. EurJ Clin Microbiol Infect Dis 1 996; 15: 799-805.
18. Sharma SD, Mullenax J, Araujo FG, et al. Western blot analysis of the antigens of Toxoplasma gondii recognized by human IgM and IgG antibodies. J Immunol 1983; 131:977-83.
19. Pratlong F, Boulot P, Issert E, et al. Fetal diagnosis of toxoplasmosis in 190 women infected during pregnancy. Prenat Diagn 1994; 14: 191-98.
20. Villena I, Aubert D, Leroux B, et al. Pyrimethamine-sulfadoxine treatment of congenital toxoplasmosis: follow-up of 78 cases between 1980 and 1997'. ScandJ Infect Dis 1998; 30: 295-300.
21. Hohlfeld P, Daffos F, Costa J-M, Thulliz P, Forestier F, Vidaud M. Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain reaction test on amniotic fluid. N Engl J Med 1994; 331: 695-99.
22. Pinon JM, Chemla C, Villena I, et al. Early neonatal diagnosis of congenital toxoplasmosis: value of comparative enzyme-linked immune filtrat ion assay immunological profiles and anu-Toxoplasma gondii immunoglobulin M (IgM) or IgG immunocapture and implications for postnatal therapeutic strategies. J Clin Microbiol 1996; 34: 579-83.
23. Kimball AC, Kean BH, Fuchs F. Congenital toxoplasmosis: a prospective study of 4048 obstetric patients. Am J Obstet Gynecol 1971; 111:211-18.